Fat cells allow melanoma cells to penetrate the dermis, from which they spread, causing fatal metastases in vital organs, TAU researchers say
Researchers at Tel Aviv University, led by Prof. Carmit Levy and Dr. Tamar Golan of the Department of Human Genetics and Biochemistry at TAU’s Sackler School of Medicine, have discovered that fat cells are involved in the transformation that melanoma cells undergo from cancer cells of limited growth in the epidermis to lethal metastatic cells attacking patients’ vital organs.
“We have answered a major question that has preoccupied scientists for years,” explains Prof. Levy. “What makes melanoma change form, turning aggressive and violent? Locked in the skin’s outer layer, the epidermis, melanoma is very treatable; it is still Stage 1, it has not penetrated the dermis to spread through blood vessels to other parts of the body and it can simply be removed without further damage.
“Melanoma turns fatal when it ‘wakes up,’ sending cancer cells to the dermis layer of skin, below the epidermis, and metastasizing in vital organs. Blocking the transformation of melanoma is one of the primary targets of cancer research today, and we now know fat cells are involved in this change.””
The research was conducted in collaboration with several senior pathologists: Dr. Hanan Vaknin of Wolfson Medical Center, and Dr. Dov Hershkowitz and Dr. Valentina Zemer of Tel Aviv Medical Center.
The study was on published July 23 in Science Signaling and is featured on the journal’s cover.
In the study, the researchers examined dozens of biopsy samples taken from melanoma patients at Wolfson Medical Center and Tel Aviv Medical Center, and observed a suspicious phenomenon: fat cells near the tumor sites.
“We asked ourselves what fat cells were doing there and began to investigate,” adds Prof. Levy. “We placed the fat cells on a petri dish near melanoma cells and followed the interactions between them.”
The researchers observed fat cells transferring proteins called cytokines, which affect gene expression, to the melanoma cells.
“Our experiments have shown that the main effect of cytokines is to reduce the expression of a gene called miRNA211, which inhibits the expression of a melanoma receptor of TGF beta, a protein that is always present in the skin,” says Prof. Levy. “The tumor absorbs a high concentration of TGF beta, which stimulates melanoma cells and renders them aggressive.”
Critically, the researchers have also found a way to block this transformation.
“It is important to note that we found the process reversible in the laboratory: When we removed the fat cells from the melanoma, the cancer cells calmed down and stopped migrating,” adds Prof. Levy.
A trial of mouse models of melanoma yielded similar results: When miRNA211 was repressed, metastases were found in other organs, while re-expressing the gene blocked metastases formation.
In the search for a potential drug based on the new discovery, the researchers experimented with therapies that are known to inhibit cytokines and TGF beta, but which have never before been used to treat melanoma.
“We are talking about substances that are currently being studied as possible treatments for pancreatic cancer, and are also in clinical trials for prostate, breast, ovarian and bladder cancers,” Dr. Golan said. “We saw that they restrained the metastatic process, and that the melanoma returned to its relatively ‘calm’ and dormant state.”
“Our findings can serve as a basis for the development of new drugs to halt the spread of melanoma — therapies that already exist, but were never used for this purpose,” concludes Prof. Levy. “In the future, we are seeking to collaborate with drug companies to enhance the development of the metastatic melanoma prevention approach.”
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- Dynamic control of tumor vasculature improves antitumor responses in a regional model of melanomaon August 6, 2020 at 2:14 am
Despite advances in therapy for melanoma, heterogeneous responses with limited durability represent a major gap in treatment outcomes. The purpose of this study was to determine whether alteration in ...
- Elios Therapeutics Personalized Cancer Vaccine Demonstrates Long-Term Survival Benefit Among High-Risk Melanoma Patients in Phase IIb Final Analysison August 5, 2020 at 4:15 am
Elios Therapeutics, a biopharmaceutical company developing innovative personalized therapeutic cancer vaccines, today announced final data from a prospective, randomized, double-blind, ...
- Popular blood pressure drug raises melanoma riskson August 4, 2020 at 9:06 pm
It has been linked to 20 per cent increased risk of malignant melanoma and a doubling of the risk of lip cancer. This year, more than 16,200 Australians will be diagnosed with a melanoma. The drug, ...
- An RNA vaccine for advanced melanomaon August 4, 2020 at 5:30 am
An RNA vaccine targeting tumour-associated antigens promotes T cell immunity in patients with advanced melanoma.
- Boston University researcher receives grant to fight melanomaon August 3, 2020 at 1:19 pm
Deborah Lang, MD, associate professor of dermatology at Boston University School of Medicine (BUSM), has been awarded a two-year, $250,000 grant from the Harry J. Lloyd Charitable Trust to further her ...
- Melanoma Research Alliance Hails FDA’s First ‘Triplet’ Combination Approval for Melanomaon August 3, 2020 at 1:16 pm
The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the decision by the U.S. Food and Drug Administration (FDA) approving Genentech’s Tecentriq ...
- AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Managementon August 3, 2020 at 5:10 am
AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, announced today the publication of the paper, "An ...
- FDA Approves Triple Drug Combo for Melanomaon July 31, 2020 at 2:46 am
The triple-therapy combination of atezolizumab plus cobimetinib and vemurafenib is now approved for BRAF V600mutation-positive advanced melanoma.
- BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab) Combination in Melanomaon July 30, 2020 at 11:00 pm
BioNTech and Regeneron plan to jointly conduct a randomized Phase 2 study combining BNT111 FixVac and Libtayo for the treatment of melanoma that has progressed after prior PD-1 blockade -- Combines ...
- FDA approves Roche's Tecentriq plus Cotellic and Zelboraf for people with advanced melanomaon July 30, 2020 at 10:00 pm
Roche ((SIX: RO, ROG, OTCQX:RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) plus ...
via Bing News